Drug profile · INN
cetrorelix acetate
CETRORELIX ACETATE
cetrorelix acetate (CETRORELIX ACETATE) is a gonadotropin-releasing hormone receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — cetrorelix acetate
- US status
- approved
- Class
- —
- Route
- SUBCUTANEOUS
- Patents
- 20
- Programs
- 3
- Data quality
- 0.89
Quick answer
cetrorelix acetate (CETRORELIX ACETATE) is a gonadotropin-releasing hormone receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Gonadotropin-releasing hormone receptor antagonist
Primary target: Gonadotropin-releasing hormone receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12410474
Methods, kits, and devices for diagnosing, prognosing, and treating psychiatric disorders in a patient
granted -
US 12377036
Melanin hair dye with thickeners
granted -
US 12370267
Inhibition of fibrosis and AF by TGF-beta inhibition in the posterior left atrium (PLA)
granted -
US 12351574
Selective ligands for modulation of GIRK channels
granted -
US 12337019
Vehicles for applying bacteria to skin, scalp, and hair
granted -
US 12331279
Systems for producing cellular immunotherapeutics and methods of use thereof
granted -
US 12319711
Spherical nucleic acids with tailored and active protein coronae
granted -
US 12291533
Substituted fused pyrimidine compounds and uses thereof
granted -
US 12281310
Use of trinucleotide repeat RNAs to treat cancer
granted -
US 12264344
Protein/oligonucleotide core-shell nanoparticle therapeutics
granted -
US 12252522
Myokines for treating cell proliferative and metabolic diseases and disorders
granted -
US 12252492
Substituted fused pyrrolo-diazepinones and uses thereof
granted -
US 12247063
Cell surface modification by coating with peptide amphiphiles (PAs)
granted -
US 12233081
Hygromycin a compounds and methods of treating spirochete diseases
granted -
US 12233080
Lipotechoic acid for immune modulation
granted -
US 12226444
Compositions comprising peptides comprising variant kinesin light chain 1 and cell-penetrating peptides
granted -
US 12226410
Methods for enhancing cellular clearance of pathological molecules via activation of the cellular protein ykt6
granted -
US 12214076
Drug delivery vehicles for atherosclerosis nanomedicine
granted -
US 12174205
Phosphatidylethanolamine-specific probes
granted -
US 12171854
Heterocyclic-dithiol click chemistry
granted
Frequently asked questions
What is cetrorelix acetate?
cetrorelix acetate (CETRORELIX ACETATE) is a gonadotropin-releasing hormone receptor antagonist. Associated with Teva Pharma GmbH. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for cetrorelix acetate?
CETRORELIX ACETATE is a marketed brand name for cetrorelix acetate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of cetrorelix acetate?
cetrorelix acetate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.